San Diego, March 18, 2025 — Erasca, a clinical-stage biotechnology company headquartered in San Diego and founded in 2018, has announced the pricing of an upsized underwritten public offering of its common stock. The offering, increased from its previously announced size, consists of 43,478,261 shares at a public offering price of $2.30 per share.
Gross proceeds are expected to reach approximately $100 million, before deducting underwriting discounts, commissions, and other offering expenses. The transaction is set to close on or about March 20, 2025, subject to customary closing conditions. The company intends to use the net proceeds from the offering to fund the development of its pipeline, which includes its lead product candidate ERAS-007, a RAF dimer inhibitor, and ERAS-601, an SHP2 inhibitor, along with other preclinical and clinical programs targeting the RAS/MAPK pathway.
Erasca’s pipeline is directed at several aggressive cancer types, including colorectal, non-small cell lung, and pancreatic cancers.
A Two-Pronged Strategy Against a Cellular Signaling Driver
The RAS/MAPK pathway is a cellular signaling chain that, when mutated, drives many aggressive cancers. Erasca’s approach is to disrupt this pathway at multiple points, a strategy designed to overcome the resistance that often develops when single-target therapies are used. ERAS-007 targets the RAF dimer, a key node in the signaling cascade.
ERAS-601 blocks SHP2, a protein that sits upstream and helps activate the pathway. Together, these two investigational compounds represent a two-pronged attack on cancers that have historically resisted treatment.
The RAS/MAPK pathway has long been a focus of cancer research because mutations in it are linked to the growth and spread of several major tumor types. Early efforts to target this pathway faced significant challenges due to the complexity of its signaling mechanisms. Advances in molecular biology have since enabled more precise interventions, including the inhibitors now in Erasca’s pipeline. The company’s work reflects a broader shift in oncology toward targeted therapies that address underlying genetic drivers of cancer rather than relying solely on traditional treatments like chemotherapy.
Both ERAS-007 and ERAS-601 are currently in development for solid tumors. The next milestones for the company are likely to come from clinical trials evaluating these candidates.
Building a War Chest for Clinical Advancement
Erasca’s latest offering bolsters a financial position that already included substantial resources. As of December 31, 2024, the company held cash, cash equivalents, and marketable securities of approximately $320 million. The March 2025 offering adds roughly $100 million in gross proceeds to that war chest.
This capital is expected to provide runway to advance the clinical trials for ERAS-007, ERAS-601, and other preclinical and clinical programs targeting the RAS/MAPK pathway. The company first went public in July 2021, raising approximately $300 million in its initial public offering.
That IPO placed Erasca among a wave of biotech firms leveraging modern science to tackle hard-to-treat diseases. The additional infusion from the March 2025 offering positions the company to continue its research and development efforts in San Diego, where research teams remain focused on bringing these therapies to patients with colorectal, non-small cell lung, and pancreatic cancers. Wall Street’s role in the offering was led by J.P.
Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C., which served as joint book-running managers. The involvement of these major investment banks underscores the level of institutional interest in Erasca’s pipeline and its targeted approach to one of oncology’s most challenging pathways.
For patients whose cancers are driven by RAS/MAPK mutations, the work being done in San Diego represents one of the few paths forward. The combination of a strengthened cash position and a multi-point strategy against a formidable cellular target gives the company a foundation to continue pursuing treatments for some of the most aggressive and treatment-resistant tumors.
